Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.45
NAS:CELG's Cash to Debt is ranked lower than
88% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:CELG: 0.45 )
Ranked among companies with meaningful Cash to Debt only.
NAS:CELG' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 1.88 Max: No Debt
Current: 0.45
Equity to Asset 0.21
NAS:CELG's Equity to Asset is ranked lower than
86% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CELG: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
NAS:CELG' s Equity to Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.59 Max: 0.92
Current: 0.21
-0.68
0.92
Interest Coverage 6.12
NAS:CELG's Interest Coverage is ranked lower than
89% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CELG: 6.12 )
Ranked among companies with meaningful Interest Coverage only.
NAS:CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.12  Med: 27.63 Max: 428.04
Current: 6.12
6.12
428.04
F-Score: 7
Z-Score: 3.98
M-Score: -2.37
WACC vs ROIC
11.52%
19.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 27.60
NAS:CELG's Operating margin (%) is ranked higher than
91% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:CELG: 27.60 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:CELG' s Operating margin (%) Range Over the Past 10 Years
Min: -64.94  Med: 28.83 Max: 32.84
Current: 27.6
-64.94
32.84
Net-margin (%) 18.95
NAS:CELG's Net-margin (%) is ranked higher than
88% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:CELG: 18.95 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:CELG' s Net-margin (%) Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 18.95
-68.02
28.88
ROE (%) 34.10
NAS:CELG's ROE (%) is ranked higher than
96% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:CELG: 34.10 )
Ranked among companies with meaningful ROE (%) only.
NAS:CELG' s ROE (%) Range Over the Past 10 Years
Min: -48.42  Med: 21.32 Max: 34.1
Current: 34.1
-48.42
34.1
ROA (%) 7.72
NAS:CELG's ROA (%) is ranked higher than
88% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:CELG: 7.72 )
Ranked among companies with meaningful ROA (%) only.
NAS:CELG' s ROA (%) Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.72
-38.07
15.8
ROC (Joel Greenblatt) (%) 177.57
NAS:CELG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:CELG: 177.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:CELG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -421.4  Med: 163.93 Max: 212.3
Current: 177.57
-421.4
212.3
Revenue Growth (3Y)(%) 21.60
NAS:CELG's Revenue Growth (3Y)(%) is ranked higher than
75% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:CELG: 21.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:CELG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 20.6  Med: 40.6 Max: 241.3
Current: 21.6
20.6
241.3
EBITDA Growth (3Y)(%) 13.10
NAS:CELG's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:CELG: 13.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:CELG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34  Med: 26.6 Max: 295.8
Current: 13.1
-34
295.8
EPS Growth (3Y)(%) 5.50
NAS:CELG's EPS Growth (3Y)(%) is ranked higher than
61% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:CELG: 5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:CELG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.8  Med: 23.55 Max: 109.7
Current: 5.5
-60.8
109.7
» NAS:CELG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CELG Guru Trades in Q3 2015

John Burbank 174,768 sh (New)
Murray Stahl 8,000 sh (+60.00%)
Louis Moore Bacon 80,000 sh (+60.00%)
RS Investment Management 130,238 sh (+22.61%)
Mario Gabelli 29,325 sh (+20.85%)
Mairs and Power 2,086 sh (+17.45%)
Ken Fisher 244,564 sh (+8.99%)
Pioneer Investments 3,637,052 sh (+3.24%)
Ken Heebner Sold Out
Lee Ainslie 2,090 sh (-6.28%)
Joel Greenblatt 6,344 sh (-18.44%)
Paul Tudor Jones 8,020 sh (-61.92%)
Jim Simons 378,633 sh (-62.39%)
» More
Q4 2015

CELG Guru Trades in Q4 2015

Steven Cohen 537,800 sh (New)
Mairs and Power 2,681 sh (+28.52%)
Lee Ainslie 2,380 sh (+13.88%)
Pioneer Investments 3,675,883 sh (+1.07%)
Ken Fisher 245,460 sh (+0.37%)
Murray Stahl 8,000 sh (unchged)
Samuel Isaly 256,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 29,270 sh (-0.19%)
RS Investment Management 129,300 sh (-0.72%)
Paul Tudor Jones 6,016 sh (-24.99%)
» More
Q1 2016

CELG Guru Trades in Q1 2016

Julian Robertson 228,840 sh (New)
Joel Greenblatt 68,917 sh (New)
Ray Dalio 4,100 sh (New)
Lee Ainslie 4,900 sh (+105.88%)
Pioneer Investments 3,821,415 sh (+3.96%)
Murray Stahl 8,000 sh (unchged)
Samuel Isaly 256,000 sh (unchged)
Mairs and Power Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 27,144 sh (-7.26%)
RS Investment Management 111,048 sh (-14.12%)
Ken Fisher 198,160 sh (-19.27%)
» More
Q2 2016

CELG Guru Trades in Q2 2016

Ronald Muhlenkamp 19,809 sh (New)
Ken Heebner 20,000 sh (New)
Jim Simons 563,038 sh (New)
Steven Cohen 21,200 sh (New)
Joel Greenblatt 317,274 sh (+360.37%)
Ray Dalio 7,300 sh (+78.05%)
Julian Robertson 379,140 sh (+65.68%)
RS Investment Management 141,861 sh (+27.75%)
Pioneer Investments 4,222,301 sh (+10.49%)
Ken Fisher 204,128 sh (+3.01%)
Murray Stahl 8,000 sh (unchged)
Lee Ainslie Sold Out
Mario Gabelli 26,988 sh (-0.57%)
Samuel Isaly 139,500 sh (-45.51%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BIIB, NAS:GILD, NAS:SHPG, NYSE:NVO, NAS:REGN, NAS:AMGN, OTCPK:CSLLY, NAS:ALXN, OTCPK:NVZMY, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:BMRN, OTCPK:UCBJF, NAS:MDVN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:ALNY » details
Traded in other countries:CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene Corp is incorporated in Delaware in 1986. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST, IMNOVID, THALOMID (inclusive of Thalidomide Celgene, ISTODAX and azacitidine for injection (generic version of VIDAZA). It owns and operates a manufacturing facility in Zofingen, Switzerland which produces the active pharmaceutical ingredient (API) for REVLIMID and THALOMID and have contracted with third-party contract manufacturers to provide backup API manufacturing services for these products. Manufacturing services for REVLIMID and THALOMID, which consist of formulation, encapsulation, packaging, warehousing and distribution, are performed at our drug product manufacturing facility in Boudry, Switzerland. The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.

Ratios

vs
industry
vs
history
P/E(ttm) 45.00
CELG's P/E(ttm) is ranked lower than
66% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. CELG: 45.00 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s P/E(ttm) Range Over the Past 10 Years
Min: 17.92  Med: 47.53 Max: 603.25
Current: 45
17.92
603.25
Forward P/E 15.27
CELG's Forward P/E is ranked higher than
59% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. CELG: 15.27 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 45.00
CELG's PE(NRI) is ranked lower than
66% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 45.00 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s PE(NRI) Range Over the Past 10 Years
Min: 17.82  Med: 47.53 Max: 482.6
Current: 45
17.82
482.6
Price/Owner Earnings (ttm) 36.49
CELG's Price/Owner Earnings (ttm) is ranked lower than
54% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. CELG: 36.49 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CELG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.44  Med: 41.88 Max: 1163.68
Current: 36.49
15.44
1163.68
P/B 14.95
CELG's P/B is ranked lower than
89% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CELG: 14.95 )
Ranked among companies with meaningful P/B only.
CELG' s P/B Range Over the Past 10 Years
Min: 4.02  Med: 9.4 Max: 23.65
Current: 14.95
4.02
23.65
P/S 8.49
CELG's P/S is ranked higher than
59% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CELG: 8.49 )
Ranked among companies with meaningful P/S only.
CELG' s P/S Range Over the Past 10 Years
Min: 5.41  Med: 10.13 Max: 27.81
Current: 8.49
5.41
27.81
PFCF 29.33
CELG's PFCF is ranked lower than
53% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. CELG: 29.33 )
Ranked among companies with meaningful PFCF only.
CELG' s PFCF Range Over the Past 10 Years
Min: 14.96  Med: 34.96 Max: 2438.33
Current: 29.33
14.96
2438.33
POCF 26.65
CELG's POCF is ranked lower than
57% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. CELG: 26.65 )
Ranked among companies with meaningful POCF only.
CELG' s POCF Range Over the Past 10 Years
Min: 13.93  Med: 32.47 Max: 1279.09
Current: 26.65
13.93
1279.09
EV-to-EBIT 32.48
CELG's EV-to-EBIT is ranked lower than
62% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. CELG: 32.48 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 34.9 Max: 156.6
Current: 32.48
-28.6
156.6
EV-to-EBITDA 27.39
CELG's EV-to-EBITDA is ranked lower than
61% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CELG: 27.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 28.85 Max: 132.5
Current: 27.39
-31.4
132.5
PEG 2.38
CELG's PEG is ranked lower than
52% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.18 vs. CELG: 2.38 )
Ranked among companies with meaningful PEG only.
CELG' s PEG Range Over the Past 10 Years
Min: 1.38  Med: 2.28 Max: 3.25
Current: 2.38
1.38
3.25
Shiller P/E 94.45
CELG's Shiller P/E is ranked lower than
71% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. CELG: 94.45 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s Shiller P/E Range Over the Past 10 Years
Min: 85.21  Med: 145.48 Max: 3211
Current: 94.45
85.21
3211
Current Ratio 4.61
CELG's Current Ratio is ranked higher than
51% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CELG: 4.61 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.33 Max: 44.53
Current: 4.61
1.35
44.53
Quick Ratio 4.37
CELG's Quick Ratio is ranked higher than
51% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CELG: 4.37 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.1 Max: 44.15
Current: 4.37
1.13
44.15
Days Inventory 378.36
CELG's Days Inventory is ranked lower than
89% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. CELG: 378.36 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 66.12  Med: 203.76 Max: 378.36
Current: 378.36
66.12
378.36
Days Sales Outstanding 54.41
CELG's Days Sales Outstanding is ranked higher than
56% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. CELG: 54.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.27
Current: 54.41
43.42
71.27
Days Payable 194.11
CELG's Days Payable is ranked higher than
82% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. CELG: 194.11 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 109.33 Max: 209.22
Current: 194.11
61.81
209.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CELG: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.7  Med: -4.9 Max: 4.5
Current: 2.1
-18.7
4.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.43
CELG's Price/Projected FCF is ranked higher than
61% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. CELG: 2.43 )
Ranked among companies with meaningful Price/Projected FCF only.
CELG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.66  Med: 5.59 Max: 122.67
Current: 2.43
1.66
122.67
Price/Median PS Value 0.85
CELG's Price/Median PS Value is ranked higher than
64% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CELG: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
CELG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.56  Med: 1.38 Max: 31
Current: 0.85
0.56
31
Price/Peter Lynch Fair Value 2.67
CELG's Price/Peter Lynch Fair Value is ranked lower than
68% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. CELG: 2.67 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CELG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.36  Med: 1.43 Max: 5.1
Current: 2.67
0.36
5.1
Earnings Yield (Greenblatt) (%) 3.06
CELG's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CELG: 3.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CELG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 2.8 Max: 6.7
Current: 3.06
0.6
6.7
Forward Rate of Return (Yacktman) (%) 19.67
CELG's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. CELG: 19.67 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CELG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.9 Max: 34.8
Current: 19.67
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $10,163
EPS (TTM) $ 2.38
Beta1.47
Short Percentage of Float0.76%
52-Week Range $93.05 - 128.39
Shares Outstanding (Mil)775.11

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 11,131 13,309 15,793 18,719
EPS ($) 5.72 7.13 9.14 11.34
EPS w/o NRI ($) 5.72 7.13 9.14 11.34
EPS Growth Rate
(3Y to 5Y Estimate)
20.44%
Dividends Per Share ($)
» More Articles for NAS:CELG

Headlines

Articles On GuruFocus.com
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 
Taking a Look at Barron’s 10 Favorite Stocks for 2016 Dec 07 2015 
Celgene: A Primer on Growth Stock Value Investing - Part 2 Nov 13 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 

More From Other Websites
What’s the Upside Potential for Gilead? Sep 26 2016
3 Health Stocks to Hold for the Next Decade Sep 26 2016
Celgene Corp. breached its 50 day moving average in a Bearish Manner : CELG-US : September 26, 2016 Sep 26 2016
S&P 500 Stocks to Buy and Hold for the Next 10 Years Sep 26 2016
The Factors behind Gilead’s Discounted Valuation Sep 23 2016
Allergan's Vitae Buy Could Spark More Interest in Kadmon Sep 23 2016
HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target Sep 22 2016
Celgene Presents Efficacy & Safety Phase II Ozanimod Data Sep 20 2016
How To Predict The Next Sarepta (FDA Approval Stock) And Win Big Sep 19 2016
RBC Says These 4 Top Biotechs Could Have Big Upside Potential Sep 19 2016
Vertex: Did Management Deliver Investors a Backhanded Slap? Sep 16 2016
Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with... Sep 16 2016
Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with... Sep 16 2016
Celgene Outspends Big Pharmas in Deals (CELG) Sep 15 2016
Celgene’s Big Bet May Pay Off (CELG) Sep 15 2016
Biotechs Help Nasdaq To Small Gain; Apple's Rise Fails To Spur Dow Sep 14 2016
Celgene's Crohn's Disease Drug Positive in Phase Ib Study Sep 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)